Dr.
Merck & Co., Inc.
Titusville, New Jersey, United States
Dr. Iyasu is the Vice President and Global Head of Pharmacoepidemiology at Merck and Co, one of the largest global pharmaceutical company in the world. In his current position at Merck, he leads a team of over 50 highly trained pharmaco-epidemiologists, molecular epidemiologists and database analysts responsible for supporting drug and vaccine clinical development, trial design, endpoint strategy and post-approval safety studies. Dr. Iyasu also leads Merck’s RWE program for regulatory applications and decision making and serves on prominent external RWE initiatives including the Duke Margolis RWE Collaborative, OPERAND initiative, ISPE Taskforce on RWE, Trancelerate Consortium, CIOMS WG XIII for RWD in regulatory decisions and the IMEDS Program. Dr. Iyasu’ s career in medicine, national and international public health, regulatory science, application of epidemiologic research methods to understanding human diseases and assessment of the safety and effectiveness of therapeutics and vaccines spans over 35 years. Prior to Joining Merck, he worked at the Food and Drug Administration in various leadership positions including as Deputy Director of Pediatric Drug Development Director of Epidemiology and Director of CDER’s Office of Pharmacovigilance and Epidemiology. Prior to FDA, he worked as an Epidemiology Team Leader in perinatal and infant health branch at the Centers for Disease Control and Prevention.
Dr. Iyasu received his medical training at the University of Delhi, India and a Master of Public Health at the Johns Hopkins University and completed a Preventive Medicine Residency and specialized field epidemiology fellowship trainings at the Centers for Disease Control and Prevention in Atlanta, Georgia.
Merck and Co. (Employment, Ownership Interest includes stock, stock options, patent or other intellectual property)
Monday, August 23, 2021
10:00 AM – 11:30 AM US Eastern Time